dronabinol oral / Generic mfg. - LARVOL DELTA

Interim analysis of a placebo controlled study of dronabinol for adults with sickle cell disease and chronic pain (ASH 2025) - "Mass spectrometry for minorcannabinoids was measured to assess for abstinence from other cannabinoids during the study period.30 subjects have been randomized (15 dronabinol/15 placebo), median age 34.3 SD 6.8 years old, 79%were female, 76% HbSS/HbSβ0, 24% HbSC/Hbβ+, 79% on hydroxyurea, 38% on crizanlizumab, and 41%on voxelotor (when it was available). In an interim analysis dronabinol was not associated with SAEs or worsened cognition, the onlyAEs were grade 1 and previously known. Personalized dose titration allowed those who were intolerantto side effects to withdraw early. Dronabinol improved social impact of disease."

Clinical • CNS Disorders • Genetic Disorders • Hematological Disorders • Neuralgia • Pain • Sickle Cell Disease

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease. (PubMed, Am J Geriatr Psychiatry) - P2 | "Adjunctive dronabinol treatment was safe and effective for treating agitation in AD."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Epilepsy • Psychiatry

Dronabinol for Agitation in Alzheimer's Disease. (PubMed, Am J Geriatr Psychiatry) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders

Therapeutic Use of Cannabis and Cannabinoids: A Review. (PubMed, JAMA) - "A meta-analysis of randomized clinical trials reported a small but significant reduction in nausea and vomiting from various causes (eg, chemotherapy, cancer) when comparing prescribed cannabinoids (eg, dronabinol, nabilone) with placebo or active comparators (eg, alizapride, chlorpromazine; standardized mean difference [SMD], -0.29 [95% CI, -0.39 to -0.18]). Clear guidance from clinicians is essential to support safe, evidence-based decision-making. Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use."

Clinical • Journal • Anorexia • Cardiovascular • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Coronary Artery Disease • Epilepsy • General Anxiety Disorder • Heart Failure • Human Immunodeficiency Virus • Infectious Disease • Insomnia • Mood Disorders • Myocardial Infarction • Oncology • Pain • Pediatrics • Psychiatry • Schizophrenia • Sleep Disorder • Substance Abuse

Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. (PubMed, Contemp Clin Trials) - "THC dosing and timing is based on prior mechanistic studies that demonstrated THC-related enhancement of extinction recall and frontolimbic circuit engagement. Aligning peak THC levels with exposure sessions maximizes potential for CB1-mediated augmentation of extinction learning. If effective, this FDA-approved augmentation strategy could be rapidly implemented to improve PE outcomes."

Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Solid Tumor

Synthetic THC And Blood Pressure (clinicaltrials.gov) - P2/3 | N=50 | Not yet recruiting | Sponsor: Mayo Clinic

New P2/3 trial

Effects of voluntary ingestion of synthetic delta-9-tetrahydrocannabinol on the hedonic value of rewarding and aversive substances and CB1 expression (Neuroscience 2025) - "The present study addresses these discrepancies by using a translational model of THC consumption, using lower oral doses of synthetic THC (Dronabinol)...Western blot data analyzed via one-way ANOVA followed by Tukey's post-hoc analysis revealed that repeated oral THC consumption dose dependently downregulated cannabinoid receptor 1 expression in the dorsal hippocampus, while no significant changes were observed in the nucleus accumbens or amygdala. These findings suggest that oral THC enhances the hedonic value of rewarding and aversive substances and provide insights into the neurobiological mechanisms that may contribute to the bidirectional use of cannabis and alcohol."

Addiction (Opioid and Alcohol) • CNS Disorders

Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized By Dizziness, Orthostatic Hypotension and Weight Loss (ASH 2023) - "B was given in combination with lenalidomide and dexamethasone (VRD) but we feel the neuropathic symptoms are more due to B since the combination of just lenalidomide and dexamethasone is not known to cause such complications...13 of 16 received VRD and 3 received Daratumumab, B and dexamethasone-based induction...Nine patients received appetite stimulants; 2 megestrol and 7 dronabinol...11 of the 16 patients had dizziness; 3 patients received fludrocortisone and one received midodrine...Transplantation without resolution of symptoms could possibly worsen the morbidity and delay post-transplant recovery. To the best of our knowledge, we are the first group to report a series of patients with this symptom complex and strongly feel it requires further study in a larger cohort."

Anorexia • Diabetes • Diabetic Neuropathy • Gastrointestinal Disorder • Hematological Malignancies • Hypotension • Metabolic Disorders • Mucositis • Multiple Myeloma • Nephrology • Neuralgia • Oncology • Orthopedics • Pain • Peripheral Neuropathic Pain • Renal Disease

A pilot study of dronabinol for the treatment of pain in sickle cell disease. (PubMed, Pilot Feasibility Stud) - P1, P2 | "In conclusion, a controlled study of dronabinol is acceptable, feasible, and safe to participants. However, a crossover design compromises participant masking. A larger, longer, controlled efficacy study without the crossover component is now being performed (NCT05519111). Trial registration NCT03978156. Date of registration: 07/26/2019."

Journal • Genetic Disorders • Hematological Disorders • Inflammation • Pain • Sickle Cell Disease

Sex Differences in Neurobehavioral Response to THC (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Medical University of South Carolina

New P2 trial • Substance Abuse

Effects of Voluntary Ingestion of Synthetic Delta-9-Tetrahydrocannabinol on the Hedonic Value of Rewarding and Aversive Substances and CB1 Receptor Expression. (PubMed, Cannabis Cannabinoid Res) - "Materials and The present study addresses these discrepancies by using a translational model of THC consumption, using lower oral doses of synthetic THC (Dronabinol)...Comparatively, THC reduced aversion to alcohol (10% and 40%) and quinine compared with vehicle. Western blot data analyzed via one-way Analysis of Variance (ANOVA) followed by Tukey's post hoc analysis revealed that repeated oral THC consumption dose-dependently downregulated cannabinoid receptor 1 receptor expression in the dorsal hippocampus, while no significant changes were observed in the nucleus accumbens or amygdala.  These findings suggest that oral THC enhances the hedonic value of rewarding and aversive substances and provide insights into the neurobiological mechanisms that may contribute to the bidirectional use of cannabis and alcohol."

Journal • Addiction (Opioid and Alcohol)

The Nausea Atlas: Identifying and Characterizing Nausea Subtypes Using Patient-Reported Information (ACG 2025) - "Ondansetron was the most effective anti-nausea medication, followed by promethazine, lorazepam, prochlorperazine, and domperidone. Marijuana was the most effective non-medication treatment, outperforming dronabinol... 745 participants (77% Female; 19% Male), reporting 1200 distinct nausea types/experiences were evaluated. The most represented age range was 31–40 years. 22% of respondents reported their nausea as severely or completely debilitating."

Clinical • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Essential oil fractions of hemp profiles at different hydro-distillation periods. (PubMed, PLoS One) - "The concentration of sesquiterpenes in the 0-5 min DT EO was 25.73%, then gradually increased to reach a plateau at 160-280 min DT (75.3-76.8%), while their concentration in the 0-180 min DT was 54.4%. The results demonstrated that hemp EO with higher concentration of monoterpenes and free of cannabinoids can be obtained by separating the initial fractions, while hemp EO with higher concentration of sesquiterpenes and cannabinoids such as cannabidiol (CBD), cannabichromene (CBC), δ8-tetrahydrocannabinol (commonly known as δ8-THC), and δ9-tetrahydrocannabinol (commonly known as δ9-THC or dronabinol) can be obtained by capturing the fraction eluted after 160 min DT."

Journal

A Synthetic Form of Cannabinoid Does Not Decrease Opioid Use After Total Knee Arthroplasty (AAHKS 2025) - "Therefore, the purpose of this study was to determine whether a synthetic delta-9-tetrahydrocannabinol (sTHC), dronabinol, decreases opioid use after TKA...The primary outcome was opioid morphine milligram equivalents (MME) at two weeks... Despite the enthusiasm for different forms of cannabis after orthopaedic surgery procedures, this s-THC does not appear to limit opioid intake after primary TKA. Based on these data, THC may offer no benefit for patients after TKA."

Orthopedics • Pain

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Yale University | Trial primary completion date: Aug 2025 ➔ Jun 2026 | Trial completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Pain

Anxiety and depressive symptoms in regular cannabis users: A literature review (ECNP 2025) - "Pharmacological options such as gabapentin, dronabinol, and nabiximols have demonstrated some efficacy for withdrawal symptoms. The use of venlafaxine in patients with depression and cannabis use is discouraged due to potential adverse outcomes [3]... Regular cannabis use is associated with increased severity and prevalence of depressive and, to a lesser extent, anxiety symptoms. This relationship appears bidirectional and is mediated by various biological and psychosocial factors. Effective treatment requires integrated approaches that address both cannabis use and co-occurring affective symptoms."

Review • CNS Disorders • Depression • Mood Disorders • Psychiatry • Substance Abuse • Suicidal Ideation

DEMURE: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (clinicaltrials.gov) - P3 | N=40 | Not yet recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Apr 2027 ➔ Aug 2027 | Initiation date: Sep 2025 ➔ Jan 2026 | Trial primary completion date: Apr 2027 ➔ Aug 2027

Trial completion date • Trial initiation date • Trial primary completion date • Substance Abuse

A Systematic Review of Management of Cramping Pain in Patients with Amyotrophic Lateral Sclerosis. (PubMed, Eur Neurol) - "The review demonstrates the scarcity of high-quality research on cramping pain management in ALS. Mexiletine emerged as the most promising pharmacological intervention, providing notable relief, while supervised exercise therapy demonstrated beneficial effects."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Pain

CRISP: Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Trial completion date: Jun 2026 ➔ May 2027 | Trial primary completion date: Jun 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Hematological Disorders • Inflammation • Pain • Sickle Cell Disease • IL4

Investigating the Antimicrobial Efficacy of Cannabinoids and Their Derivatives Against Neisseria Gonorrhoeae by Computational Analysis. (PubMed, Biology (Basel)) - "Dronabinol, Cannabinolic acid A (CBNA), Cannabigerolic acid (CBGA), and Ferruginene C are derivatives identified. Drug-likeness assessments were conducted to evaluate the pharmacokinetic and toxicity properties of the cannabinoids and compared against the antibiotics."

Journal • Infectious Disease

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Baylor College of Medicine | Initiation date: May 2025 ➔ Jan 2026 | Trial primary completion date: Dec 2027 ➔ Dec 2026

Trial initiation date • Trial primary completion date • Endometriosis • Gynecology • Pain • Women's Health

Chemical Composition and Antioxidant Activity of the Stembark Essential Oils of Two Cannabis sativa L. Cultivars from Komga, South Africa. (PubMed, Int J Mol Sci) - "The EOs of both cultivars contained twenty compounds, notably Cannabidiol (0.25-85.03%), Caryophyllene oxide (1.27-19.58%), Caryophyllene (0.64-16.61%), Humulene (0.37-8.15%), Octacosane (3.37-6.55%), Humulene-1,2-epoxide (0.45-5.78%), Nerolidol (0.32-4.99%), Palmitic acid (1.45-4.45%), Tetracosane (1.75-2.91%), Dronabinol (0.86-2.86%), Cannabinol (0.54-1.64%), 7-epi-γ-eudesmol (0.53-1.00%), Guaiol (0.37-0.66%), Linoleic acid (0.22-0.60%), γ-Selinene (0.15-0.48%), β-Eudesmol (0.34-0.50%), and Linalool (0.24-0.30%)...It can be inferred from this study that the EOs from the stembark of C. sativa contain promising compounds, such as Cannabinol, Cannabidiol, and Linalool, which might be responsible for the displayed antioxidant activity of the oils. Thus, the study findings underscore the biological importance of C. sativa stembark in the management of oxidative stress-related conditions."

Journal

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Food and Drug Administration (FDA)

New P1 trial

A Review on Sarcopenia, Cachexia, and Aging. (PubMed, J Assoc Physicians India) - "The treatment consists of appetite stimulants, dietary and nutritional supplementation, tailored exercise, and anti-inflammatory drugs. Megestrol acetate, an appetite stimulant, and dronabinol (Marinol), a narcotic drug used to treat nausea and vomiting in patients with cachexia."

Journal • Cachexia • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • Sarcopenia

DROSA: DRonabinol Treatment of OSA (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: VA Office of Research and Development | Not yet recruiting ➔ Recruiting

Enrollment open • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder